ATE360424T1 - 2,3,4,5-tetrahydrobenzo[fö]1,4öoxazepin-5- carbonsäureamid derivate als gamma-secretase inhibitoren zur behandlung von alzheimer - Google Patents

2,3,4,5-tetrahydrobenzo[fö]1,4öoxazepin-5- carbonsäureamid derivate als gamma-secretase inhibitoren zur behandlung von alzheimer

Info

Publication number
ATE360424T1
ATE360424T1 AT04732944T AT04732944T ATE360424T1 AT E360424 T1 ATE360424 T1 AT E360424T1 AT 04732944 T AT04732944 T AT 04732944T AT 04732944 T AT04732944 T AT 04732944T AT E360424 T1 ATE360424 T1 AT E360424T1
Authority
AT
Austria
Prior art keywords
tetrahydrobenzo
alzheimer
gamma
treatment
acid amide
Prior art date
Application number
AT04732944T
Other languages
English (en)
Inventor
Guido Galley
Robert Alan Goodnow Jr
Jens Uwe Peters
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE360424T1 publication Critical patent/ATE360424T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04732944T 2003-05-19 2004-05-14 2,3,4,5-tetrahydrobenzo[fö]1,4öoxazepin-5- carbonsäureamid derivate als gamma-secretase inhibitoren zur behandlung von alzheimer ATE360424T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011040 2003-05-19

Publications (1)

Publication Number Publication Date
ATE360424T1 true ATE360424T1 (de) 2007-05-15

Family

ID=33442730

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04732944T ATE360424T1 (de) 2003-05-19 2004-05-14 2,3,4,5-tetrahydrobenzo[fö]1,4öoxazepin-5- carbonsäureamid derivate als gamma-secretase inhibitoren zur behandlung von alzheimer

Country Status (19)

Country Link
US (1) US7060698B2 (de)
EP (1) EP1631296B1 (de)
JP (1) JP4510021B2 (de)
KR (1) KR100731368B1 (de)
CN (1) CN1794997B (de)
AR (1) AR044363A1 (de)
AT (1) ATE360424T1 (de)
AU (1) AU2004238037B2 (de)
BR (1) BRPI0410647A (de)
CA (1) CA2524640C (de)
CL (1) CL2004001068A1 (de)
DE (1) DE602004006118T2 (de)
ES (1) ES2285458T3 (de)
MX (1) MXPA05012368A (de)
MY (1) MY143953A (de)
PL (1) PL1631296T3 (de)
RU (1) RU2332408C2 (de)
TW (1) TWI290550B (de)
WO (1) WO2004100958A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
EP1812007B1 (de) 2004-11-02 2011-09-07 Northwestern University Pyridazinverbindungen und verfahren
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
CN101115730A (zh) * 2004-12-14 2008-01-30 阿斯利康(瑞典)有限公司 新分子探针
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8855099B2 (en) 2007-03-19 2014-10-07 Qualcomm Incorporated Selective phase connection establishment
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
RU2345078C1 (ru) * 2007-06-19 2009-01-27 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция, способ получения
JP5275315B2 (ja) * 2010-10-01 2013-08-28 学校法人近畿大学 新規化合物及びβ−セクレターゼ阻害剤
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
NO3175985T3 (de) * 2011-07-01 2018-04-28
WO2019173761A1 (en) 2018-03-09 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
ATE290545T1 (de) * 1996-12-06 2005-03-15 Vertex Pharma Inhibitoren des interleukin-1beta konvertierenden enzyms
CZ20024151A3 (cs) 2000-06-23 2003-05-14 Takeda Chemical Industries, Ltd. Benzoxazepinony, způsob jejich výroby a použití
JP2002080468A (ja) * 2000-06-23 2002-03-19 Takeda Chem Ind Ltd ベンゾオキサゼピン化合物
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
US7060798B2 (en) * 2002-05-13 2006-06-13 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Modified protein adhesives and lignocellulosic composites made from the adhesives
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives

Also Published As

Publication number Publication date
AR044363A1 (es) 2005-09-07
WO2004100958A1 (en) 2004-11-25
CA2524640A1 (en) 2004-11-25
RU2005139529A (ru) 2006-08-10
EP1631296B1 (de) 2007-04-25
PL1631296T3 (pl) 2007-08-31
CA2524640C (en) 2011-10-11
CN1794997A (zh) 2006-06-28
BRPI0410647A (pt) 2006-07-04
AU2004238037A1 (en) 2004-11-25
CN1794997B (zh) 2010-05-12
TW200510355A (en) 2005-03-16
KR100731368B1 (ko) 2007-06-21
MY143953A (en) 2011-07-29
EP1631296A1 (de) 2006-03-08
US7060698B2 (en) 2006-06-13
US20040235819A1 (en) 2004-11-25
JP4510021B2 (ja) 2010-07-21
AU2004238037B2 (en) 2009-11-26
MXPA05012368A (es) 2006-02-02
CL2004001068A1 (es) 2005-04-15
KR20060003107A (ko) 2006-01-09
DE602004006118T2 (de) 2008-01-03
ES2285458T3 (es) 2007-11-16
DE602004006118D1 (de) 2007-06-06
TWI290550B (en) 2007-12-01
JP2007501261A (ja) 2007-01-25
RU2332408C2 (ru) 2008-08-27

Similar Documents

Publication Publication Date Title
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
ATE360424T1 (de) 2,3,4,5-tetrahydrobenzo[fö]1,4öoxazepin-5- carbonsäureamid derivate als gamma-secretase inhibitoren zur behandlung von alzheimer
PT1041072E (pt) Acidos dioxociclopentil hidroxamicos
DE602005022113D1 (de) Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
NZ596579A (en) Bace inhibitors
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ZA200705018B (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE60228317D1 (de) N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
DE602004029465D1 (de) Externes Präparat zur Behandlung von Fusspilz
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE502004009152D1 (de) Verfahren zur herstellung von derivaten des 4a,5,9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
DE602006005640D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1631296

Country of ref document: EP